{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:27:17Z","timestamp":1767706037951},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Claudins are integral membrane proteins that are involved in forming cellular tight junctions. One member of the claudin family, claudin-3, has been shown to be overexpressed in breast, ovarian, and pancreatic cancer. Here we use immunohistochemistry to evaluate its expression in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), normal tissue adjacent to prostatic adenocarcinoma (NAC), primary prostatic adenocarcinoma (PCa), and metastatic prostatic adenocarcinoma (Mets).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Tissue microarrays were immunohistochemically stained for claudin-3, with the staining intensities subsequently quantified and statistically analyzed using a one-way ANOVA with subsequent Tukey tests for multiple comparisons or a nonparametric equivalent. Fifty-three cases of NAC, 17 cases of BPH, 35 cases of PIN, 107 cases of PCa, and 55 cases of Mets were analyzed in the microarrays.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>PCa and Mets had the highest absolute staining for claudin-3. Both had significantly higher staining than BPH (p &lt; 0.05 in both cases) and NAC (p &lt; 0.05 in both cases). PIN had a lower, but non-significant, staining score than PCa and Mets, but a statistically higher score than both BPH and NAC (p &lt; 0.05 for both cases). No significant differences were observed between PCa, Mets, and PIN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>To our knowledge, this represents one of the first studies comparing the immunohistochemical profiles of claudin-3 in PCa and NAC to specimens of PIN, BPH, and Mets. These findings provide further evidence that claudin-3 may serve as an important biomarker for prostate cancer, both primary and metastatic, but does not provide evidence that claudin-3 can be used to predict risk of metastasis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1746-1596-6-12","type":"journal-article","created":{"date-parts":[[2011,1,22]],"date-time":"2011-01-22T07:14:04Z","timestamp":1295680444000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma"],"prefix":"10.1186","volume":"6","author":[{"given":"Tanner L","family":"Bartholow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma R","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Becich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil V","family":"Parwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,21]]},"reference":[{"issue":"5","key":"361_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322\/caac.20073.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"361_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1097\/01.ju.0000177470.84735.55","volume":"174","author":"BR Konety","year":"2005","unstructured":"Konety BR, Bird VY, Deorah S, Dahmoush L: Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol. 2005, 174 (5): 1785-1788. 10.1097\/01.ju.0000177470.84735.55. discussion 1788","journal-title":"J Urol"},{"issue":"5","key":"361_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/ijc.2910200506","volume":"20","author":"N Breslow","year":"1977","unstructured":"Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al.: Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977, 20 (5): 680-688. 10.1002\/ijc.2910200506.","journal-title":"Int J Cancer"},{"issue":"1","key":"361_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/00365598009181186","volume":"14","author":"B Holund","year":"1980","unstructured":"Holund B: Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980, 14 (1): 29-35. 10.3109\/00365598009181186.","journal-title":"Scand J Urol Nephrol"},{"issue":"6","key":"361_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ijc.2910290602","volume":"29","author":"R Yatani","year":"1982","unstructured":"Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P: Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982, 29 (6): 611-616. 10.1002\/ijc.2910290602.","journal-title":"Int J Cancer"},{"issue":"13","key":"361_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","volume":"94","author":"R Etzioni","year":"2002","unstructured":"Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002, 94 (13): 981-990.","journal-title":"J Natl Cancer Inst"},{"key":"361_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-5-45","volume":"5","author":"UR Chandran","year":"2005","unstructured":"Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J: Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005, 5: 45-10.1186\/1471-2407-5-45.","journal-title":"BMC Cancer"},{"key":"361_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1749-6632.2000.tb05235.x","volume":"915","author":"S Tsukita","year":"2000","unstructured":"Tsukita S, Furuse M: The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci. 2000, 915: 129-135. 10.1111\/j.1749-6632.2000.tb05235.x.","journal-title":"Ann N Y Acad Sci"},{"key":"361_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.physiol.68.040104.131404","volume":"68","author":"CM Van Itallie","year":"2006","unstructured":"Van Itallie CM, Anderson JM: Claudins and epithelial paracellular transport. Annu Rev Physiol. 2006, 68: 403-429. 10.1146\/annurev.physiol.68.040104.131404.","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"361_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/35067088","volume":"2","author":"S Tsukita","year":"2001","unstructured":"Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001, 2 (4): 285-293. 10.1038\/35067088.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"361_CR11","doi-asserted-by":"crossref","first-page":"G477","DOI":"10.1152\/ajpgi.2000.279.3.G477","volume":"279","author":"M Cereijido","year":"2000","unstructured":"Cereijido M, Shoshani L, Contreras RG: Molecular physiology and pathophysiology of tight junctions. I. Biogenesis of tight junctions and epithelial polarity. Am J Physiol Gastrointest Liver Physiol. 2000, 279 (3): G477-482.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"361_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev.physiol.60.1.161","volume":"60","author":"M Cereijido","year":"1998","unstructured":"Cereijido M, Valdes J, Shoshani L, Contreras RG: Role of tight junctions in establishing and maintaining cell polarity. Annu Rev Physiol. 1998, 60: 161-177. 10.1146\/annurev.physiol.60.1.161.","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"361_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/09687680210129236","volume":"19","author":"F D'Atri","year":"2002","unstructured":"D'Atri F, Citi S: Molecular complexity of vertebrate tight junctions (Review). Mol Membr Biol. 2002, 19 (2): 103-112.","journal-title":"Mol Membr Biol"},{"issue":"21","key":"361_CR14","doi-asserted-by":"publisher","first-page":"9603","DOI":"10.1158\/0008-5472.CAN-05-2782","volume":"65","author":"PJ Morin","year":"2005","unstructured":"Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005, 65 (21): 9603-9606. 10.1158\/0008-5472.CAN-05-2782.","journal-title":"Cancer Res"},{"key":"361_CR15","unstructured":"Ouban A, Ahmed AA: Claudins in human cancer: a review. Histol Histopathol. 25 (1): 83-90."},{"issue":"22","key":"361_CR16","first-page":"6281","volume":"60","author":"CD Hough","year":"2000","unstructured":"Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60 (22): 6281-6287.","journal-title":"Cancer Res"},{"issue":"11","key":"361_CR17","first-page":"1185","volume":"22","author":"YL Choi","year":"2007","unstructured":"Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, et al.: Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol. 2007, 22 (11): 1185-1195.","journal-title":"Histol Histopathol"},{"key":"361_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2407-6-186","volume":"6","author":"KJ Hewitt","year":"2006","unstructured":"Hewitt KJ, Agarwal R, Morin PJ: The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006, 6: 186-10.1186\/1471-2407-6-186.","journal-title":"BMC Cancer"},{"issue":"3","key":"361_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/jcp.2005.028589","volume":"59","author":"Y Soini","year":"2006","unstructured":"Soini Y, Kinnula V, Kahlos K, Paakko P: Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol. 2006, 59 (3): 250-254. 10.1136\/jcp.2005.028589.","journal-title":"J Clin Pathol"},{"issue":"11","key":"361_CR20","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/modpathol.2008.116","volume":"21","author":"M Lechpammer","year":"2008","unstructured":"Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ: The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol. 2008, 21 (11): 1320-1329. 10.1038\/modpathol.2008.116.","journal-title":"Mod Pathol"},{"issue":"4","key":"361_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.humpath.2006.11.007","volume":"38","author":"GM Sheehan","year":"2007","unstructured":"Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Ross JS: Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007, 38 (4): 564-569. 10.1016\/j.humpath.2006.11.007.","journal-title":"Hum Pathol"},{"issue":"2","key":"361_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10735-006-9054-5","volume":"38","author":"A Kajdacsy-Balla","year":"2007","unstructured":"Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, et al.: Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol. 2007, 38 (2): 113-121. 10.1007\/s10735-006-9054-5.","journal-title":"J Mol Histol"},{"key":"361_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1746-1596-2-41","volume":"2","author":"M Yin","year":"2007","unstructured":"Yin M, Dhir R, Parwani AV: Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol. 2007, 2: 41-10.1186\/1746-1596-2-41.","journal-title":"Diagn Pathol"},{"key":"361_CR24","doi-asserted-by":"crossref","unstructured":"Seo KW, Kwon YK, Kim BH, Kim CI, Chang HS, Choe MS, Park CH: Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer. Korean J Urol. 51 (4): 239-244. 10.4111\/kju.2010.51.4.239.","DOI":"10.4111\/kju.2010.51.4.239"},{"issue":"3","key":"361_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/sj.bjc.6604486","volume":"99","author":"KA Landers","year":"2008","unstructured":"Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA: Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer. 2008, 99 (3): 491-501. 10.1038\/sj.bjc.6604486.","journal-title":"Br J Cancer"},{"issue":"1","key":"361_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1309\/U77A6BTEXVCA5D0E","volume":"130","author":"K Nakanishi","year":"2008","unstructured":"Nakanishi K, Ogata S, Hiroi S, Tominaga S, Aida S, Kawai T: Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract. Am J Clin Pathol. 2008, 130 (1): 43-49. 10.1309\/U77A6BTEXVCA5D0E.","journal-title":"Am J Clin Pathol"},{"key":"361_CR27","unstructured":"Jung H, Jun KH, Jung JH, Chin HM, Park WB: The Expression of Claudin-1, Claudin-2, Claudin-3, and Claudin-4 in Gastric Cancer Tissue. J Surg Res."},{"issue":"7","key":"361_CR28","first-page":"2567","volume":"9","author":"LB Rangel","year":"2003","unstructured":"Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003, 9 (7): 2567-2575.","journal-title":"Clin Cancer Res"},{"issue":"28","key":"361_CR29","doi-asserted-by":"publisher","first-page":"26233","DOI":"10.1074\/jbc.M502003200","volume":"280","author":"T D'Souza","year":"2005","unstructured":"D'Souza T, Agarwal R, Morin PJ: Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem. 2005, 280 (28): 26233-26240.","journal-title":"J Biol Chem"},{"issue":"16","key":"361_CR30","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1158\/0008-5472.CAN-05-1036","volume":"65","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, D'Souza T, Morin PJ: Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65 (16): 7378-7385. 10.1158\/0008-5472.CAN-05-1036.","journal-title":"Cancer Res"},{"issue":"21","key":"361_CR31","first-page":"7878","volume":"61","author":"H Long","year":"2001","unstructured":"Long H, Crean CD, Lee WH, Cummings OW, Gabig TG: Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001, 61 (21): 7878-7881.","journal-title":"Cancer Res"},{"issue":"7","key":"361_CR32","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/cncr.22536","volume":"109","author":"AD Santin","year":"2007","unstructured":"Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S: Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer. 2007, 109 (7): 1312-1322. 10.1002\/cncr.22536.","journal-title":"Cancer"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-6-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T06:27:25Z","timestamp":1630477645000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-6-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-6-12","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,21]]},"assertion":[{"value":"2 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"12"}}